APA (7th ed.) Citation

HX, H., Y, G., JC, F., QH, Z., XX, W., B, B., . . . HQ, H. (2021). VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. Oncoimmunology, 10(1), 1907059. https://doi.org/10.1080/2162402X.2021.1907059

Chicago Style (17th ed.) Citation

HX, He, et al. "VISTA and PD-L1 Synergistically Predict Poor Prognosis in Patients with Extranodal Natural Killer/T-cell Lymphoma." Oncoimmunology 10, no. 1 (2021): 1907059. https://doi.org/10.1080/2162402X.2021.1907059.

MLA (9th ed.) Citation

HX, He, et al. "VISTA and PD-L1 Synergistically Predict Poor Prognosis in Patients with Extranodal Natural Killer/T-cell Lymphoma." Oncoimmunology, vol. 10, no. 1, 2021, p. 1907059, https://doi.org/10.1080/2162402X.2021.1907059.